Table 2.
Characteristics of IPF patients and controls.
| IPF (n = 38) | Controls (n = 77) | |
|---|---|---|
| Age (Mean ± SD) | 73.8 ±7.83 | 55.6 ± 6.7 |
| Male/Female, n (%) | 29/9 (76%/24%) |
39/38 (51%/49%) |
| Smoking history | ||
| - Never smokers (n, %) | 8 (21%) | 37 (48%) |
| - Ex-smokers (n, %) | 29 (76%) | - |
| - Current smokers (n, %) | 1 (3%) | 40 (52%) |
| Lung function | ||
| - FVC (% predicted) | 80.8 ± 20.2 | 113 ± 14.4 |
| - FEV1 (% predicted) | 81.2 ± 17.9 | 103 ± 13.9 |
| - DLCO (% predicted) | 50.4 ± 11.8 | 86.5 ± 14.0 |
| - TLC (% predicted) | 64.3 ± 11.2 | 107 ± 11.0 |
| CPI (Mean ± SD) | 43.0 ± 10.7 | NA |
| GAP stage (n, %) | NA | |
| 1 | 21 (55%) | |
| 2 | 17 (45%) | |
| 3 | 0 (0%) | |
| Treatment with antifibrotics at serum sampling | NA | |
| - Treated baseline and treated follow-up | 12 (32%) | |
| - Untreated baseline and treated follow-up | 13 (34%) | |
| - Untreated baseline and untreated follow-up | 11 (29%) | |
| - Treated baseline and untreated follow-up | 2 (5%) |
IPF: Idiopathic pulmonary fibrosis; FVC %:forced vital capacity, % predicted; FEV1 %: forced expiratory volume in 1 s, % predicted; DLCO %:diffusing capacity of carbon monoxide, % predicted; TLC %: total lung capacity,% predicted; CPI: composite physiological index; GAP-stage: gender-age-physiology stage for IPF.